The use of valproate intravenously;Utilizacion del valproato por via intravenosa

Revista de Neurologia

Volumn 29, Issue 8, 1999, Pages 744-753

  Adin J ^a   Arteaga, R ^a   Herranz, J L ^a   Armijo, J A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antiepileptic drugs; Dosage; Intravenous route; Pharmacokinetics; Status epilepticus; Tolerability; Use; Valproate

Indexed keywords

DIAZEPAM; PHENYTOIN; VALPROIC ACID; ANTICONVULSIVE AGENT;

ANTICONVULSANT THERAPY; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTIC STATE; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; SEIZURE; ADOLESCENT; ADULT; AGED; BLOOD; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; EPILEPSY; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; EPILEPSY; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MIDDLE AGED; VALPROIC ACID;

EID: 0033576023     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2908.99311     Document Type: Review

References (57)

1. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-72.
2. Pellock JM. Standard approach to antiepileptic drug treatment in the United States. Epilepsia 1994; 35 (Suppl 4): 11-8.
3. Bourgeois BFD. Antiepileptic drugs in pediatric practice. Epilepsia 1995; 36 (Suppl 2): 34-45.
4. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995; 36 (Suppl 2): 13-26.
5. Herranz JL. Epilepsias. Tratamiento medicamentoso. En Fejerman N, Fernández-Álvarez E, eds. Neurología pediátrica, 2 ed. Madrid: Panamericana; 1997. p. 574-9.
6. Armijo JA, Herranz JL. Fármacos antiepilépticos. Medicine 1998; 7: 4605-16.
7. Moore AJ, Bell BA, Berry DJ. Intravenous sodium valproate in neurosurgery: repeat dose pharmacokinetic study and safety assessment in neurosurgical patients. In Chadwick D, ed. Fourth International Symposium on Sodium Valproate and Epilepsy. London: Royal Society of Medicine Services; 1989. p. 204-7.
8. Price DJ. Intravenous valproate: experience in neurosurgery. In Chadwick D, ed. Fourth International Symposium on Sodium Valproate and Epilepsy. London: Royal Society of Medicine Services; 1989. p. 197-203.
9. Marlow N, Cooke RWI. Intravenous sodium valproate in the neonatal intensive care unit. In Chadwick D, ed. Fourth International Symposium on Sodium Valproate and Epilepsy. London: Royal Society of Medicine Services; 1989. p. 208-10.
10. PDR (Physician Desk Reference). Montreal: Medical Economics Co.; 1999. p. 417-8.
11. Dewinski O, Leppik I, Willmore LJ, Pellock JM, Dean C, Gates J, et al. Safety of intravenous valproate. Ann Neurol 1995; 38: 670-4.
12. Ramsay RE, Uthman B, Leppik IE, Pellock JM, Wilder BJ, Morris D, et al. The tolerability and safety of valproate sodium injection given as an intravenous infusion. J Epilepsy 1997; 10: 187-93.
13. Patrias JM, Gates JR, Ritter FJ, Penovich PE, Frost MD, Moriarty GL. Safety of intravenous valproate. Epilepsia 1993; 34 (Suppl 6): 111.
14. Anderson GD, Gidal BE, Sumida WK, Hendryx RJ, James DM, Ensign RH, et al. Valproate pharmacokinetics in post-traumatic head injury patients. Clin Pharmacol Ther 1992; 51: 133.
15. Morton LD, Pellock JM. Treatment options for acute seizure care: use of new formulations. CNS Drugs 1998; 10: 405-16.
16. Bebin EM. Additional modalities for treating acute seizures in children: overview. J Child Neurol 1998; 13 (Suppl 1): 23-6.
17. Leroy RF, Harvey J, Zutter L, North RR. Rapid intravenous valproic acid loading: dosage, blood levels, and safety. Epilepsia 1998; 39 (Suppl 6): 49.
18. Exil G, Brown WD, Ferri R, Caruso J, Gascon GG. Safety and efficacy of intravenous rapid infusion of valproate sodium in pediatrics patients: a report of 13 cases. Epilepsia 1998; 39 (Suppl 6): 127.
19. Dodson WE, DeLorenzo RJ, Pedley TA, Shinnar S, Treiman DM, Wannamaker BB. Treatment of convulsive status epilepticus: recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270: 854-9.
20. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatment for generalized convulsive status epilepticus. N Engl J Med 1998; 339: 792-8.
21. Herranz JL. Enfoque terapéutico de las convulsiones agudas y de los status convulsivos. En Herranz JL, Armijo JA, eds. Actualización de las epilepsias (II). Barcelona: Consulta; 1992. p. 167-78.
22. Delgado-Escueta AV, Fong CY. Status epilepticus: recent trends and prospects. Neurologia 1997; 12 (Suppl 6): 62-73.
23. Treiman DM. Treatment of status epilepticus. In Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 1317-23.
24. Lowenstein DH, Aldredge BK. Status epilepticus. N Engl J Med 1998; 338: 970-6.
25. Salas Puig J, Mateos Marcos V. Status epilepticus. En Cruz Campos GA, ed. Manual de terapia en epilepsias de adultos y ancianos. Barcelona: Sociedad Española de Neurología; 1998. p. 81-91.
26. Willmore LJ. Epilepsy emergencies: the first seizure and status epilepticus. Neurology 1998; 51 (Suppl 4): S34-8.
27. Tasker RC. Emergency treatment of acute seizures and status epilepticus. Arch Dis Child 1998; 79: 78-83.
28. Pellock JM. Management of acute seizure episodes. Epilepsia 1998; 39 (Suppl 1): 28-35.
29. Campistol J, López JA, Ruiz S. Estado de mal epiléptico en la infancia. Revisión casuística y protocolo de tratamiento. Rev Neurol 1997; 25 (Supl 4): 446-52.
30. Berkovic SF, Bladin PF. Absence status in adults. Clin Exp Neurol 1983; 19: 198-207.
31. Iivanainen M, Bergstrom L, Nuutila A, Viukari M. Psychosis-like absence status of elderly patients: successful treatment with sodium valproate. J Neurol Neurosurg Psychiatry 1984; 47: 965-9.
32. Alehan FK, Morton LD, Pellock JM. Treatment of absence status with intravenous valproate. Neurology 1999; 52: 889-90.
33. Kaplan PW. Intravenous valproate treatment of generalized nonconvulsive status epilepticus. Clin Electroencephalogr 1999; 30: 1-4.
34. Yasuhara A, Yoshida H, Hatanaka T, Sugimoto T, Kobayashi Y, Dyken E. Epilepsy with continuous spike-waves during slow sleep and its treatment. Epilepsia 1991; 32: 59-62.
35. Campistol J, Fernández A, Ortega J. Estado de mal convulsivo en el nino. Experiencia con valproato endovenoso. Actualización del protocolo de tratamiento. Rev Neurol 1999; 29: 359-65.
36. Leppick IE, Sherwin A. Intravenous valproate efficacy and brain concentrations. Neurology 1989; 39 (Suppl 1): S293.
37. Hönack D, Löscher W. Intravenous valproate onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res 1992; 13: 215-21.
38. Giraud M, Gras P, Escousse A, Dumas R, Venaud G. Use of injectable valproic acid in status epilepticus: a pilot study. Drug Invest 1993; 5: 154-9.
39. Czapinski P, Tercynski A. Intravenous valproic acid administration in status epilepticus. Neurol Neurochir Pol 1998; 32: 11-22.
40. Mizrahi EM. Treatment of neonatal seizures. In Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 1295-303.
41. Wheless JW, Venkataraman V. Safety of high intravenous valproate loading doses in epilepsy patients. J Epilepsy 1998; 11: 319-24.
42. Miles DK, Melvin JJ. Safety of intravenous valproate in pediatric patients. Epilepsia 1998; 39 (Suppl 6): 48.
43. Mueed S, Naritoku DK. Intravenous loading and replenishment therapy with valproic acid. Epilepsia 1998; 39 (Suppl 6): 128.
44. Nitsche V, Mascher H. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia 1982; 23: 153-62.
45. Gallo BV. Safety and pharmacokinetic profile of high-dose i.v. bolus administration of valproic acid (Depakon). Epilepsia 1998; 39 (Suppl 6): 49.
46. Granneman GR, Lamm JE, Cavanaugh JH. Assessment of pharmacokinetics of sodium valproate injectable. Epilepsia 1989; 30: 668.
47. Lowe MR, DeToledo JC, Velarza N, Ramsay RE. Efficacy, safety, and tolerability of fast i.v. loading of valproate in patients with seizures and status epilepticus. Epilepsia 1998; 39 (Suppl 6): 235.
48. Venkataraman V, Wheless JW. Safety of rapid iv loading doses of valproate. Epilepsia 1998; 39 (Suppl 6): 50.
49. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21: 736-43.
50. Perucca E, Gatti G, Frigo GM, Crema A. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol 1978; 5: 313-8.
51. Perucca E, Gatti G, Frigo GM, Crema A. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 495-9.
52. Löscher W, Hönack D. Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ('controlled release') administration in a model of generalized seizures in rats. Epilepsia 1995; 36: 929-37.
53. Wieser HG. Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res 1991; 9: 154-9.
54. Ieiri I, Morioka T, Ichimiya T, Nishio S. Fukui M, Ohtsubo K, et al. Pharmacokinetic study of valproic acid sustained-release preparation in patients undergoing brain surgery. Ther Drug Monit 1995; 17: 6-11.
55. Gjerloff I, Arentsen J, Alving J, Secher BG. Monodose versus 3 daily doses of sodium valproate: a controlled trial. Acta Neurol Scand 1984; 69: 120-4.
56. Pisani F, Oteri G, Caputo M, Di Perri R. Diurnal fluctuations in plasma drug levels at steady-state: studies with valproic acid and carbamazepine. In Dreifus FE, Meinardi H, Stefan H, eds. Chronopharmacology in therapy of the epilepsies. New York: Raven Press; 1990. p. 129-42.
57. Frey HH, Löscher W. Distribution of valproate across the interface between blood and cerebro-spinal fluid. Neuropharmacology 1978; 17: 637-42.